The problem is documented. So is the fix.
Three peer-reviewed trials measured exactly what happens to lean mass on GLP-1 therapy. The numbers are specific. So is the response.
Of lean body mass lost on semaglutide over 68 weeks, alongside 19.3% of fat mass.
Source: STEP 1 body-composition substudy, Wilding et al., 2021
About 25% of the weight lost on tirzepatide was lean mass, not fat.
Source: SURMOUNT-1 DXA analysis, 2025
Creatine plus resistance training increased lean tissue and strength in 721 adults aged 57 to 70.
The trials show that lean mass loss is a documented side effect of GLP-1-assisted weight loss, not a hypothetical risk. The same body of evidence identifies the documented levers: sufficient protein intake, creatine supplementation, and resistance training. Anchor handles the nutrition side. You can read more about how the two sides work together on the GLP-1 guide, or go straight to the lean muscle collection.
First reviews
Anchor launched in September 2026. The first customers to leave a verified review receive $10 off their next order. Email hello@anchor.thisisomni.ai with your order number and the word REVIEW in the subject line. Reviews will appear on this page as they come in, unedited.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
